Long-term survival of high-risk melanoma patients immunized with a Hyper-IL-6-modified allogeneic whole-cell vaccine after complete resection

Bibliography

• Garbe C, Eigrntler ThK, Keilholz U, Systemic review of medical treatment in melanoma: current status and future prospects. Oncologist 2011;16:5-24
   PubMed Web of Science ®Google Scholar
• Smith FO, Downey SG, Klapper JA, Treatment of metastatic melanoma using Interleukin-2 alone or in conjunction with vaccines. Clin Cancer Res 2008;14:5610-18
   PubMed Web of Science ®Google Scholar
• Sosman JA, Kim KB, Schuchter L, Survival in BRAF V600-mutant advanced melanoma treated with Vemurafenib. N Engl J Med 2012;366:707-14
   PubMed Web of Science ®Google Scholar
• Morgan RA, Dudley ME, Wunderlich JR, Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 2006;314:126-9
   PubMed Web of Science ®Google Scholar
• Hodi FS, O'Day S, McDermont DF, Improved survival with ipilumumab in patients with metastatic melanoma. N Engl J Med 2010;363:711-23
   PubMed Web of Science ®Google Scholar
• Kirkwood JM, Strawderman MH, Ernstoff MS, Interferon alfa-2b adjuvant therapy of high risk resected cutaneous melanoma: the Eastern Cooperative Oncology group Trial EST 1684. J Clin Oncol 1996;14:7-17
   PubMed Web of Science ®Google Scholar
• Davar D, Tarhini A, Kirkwood JM. Adjuvant therapy for melanoma. Cancer J 2012;18:192-202
   PubMed Web of Science ®Google Scholar
• Schwartzentruber DJ, Lawson DH, Richards JM, gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N Engl J Med 2011;364:2119-27
   PubMed Web of Science ®Google Scholar
• Kantoff PW, Higano CS, Shore ND, Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010;363:411-22
   PubMed Web of Science ®Google Scholar
• Feun LG, Guttermann J, Burgess MA, The natural history of resectable metastatic melanoma. Cancer 1982;50:1656-63
   PubMed Web of Science ®Google Scholar
• Leung AM, Hari DM, Morton DL. Surgery for distant melanoma metastasis. Cancer J 2012;18:176-84
   PubMed Web of Science ®Google Scholar
• Eggermont AMM, Testori A, Maio M, Anti-CTL-4 antibody adjuvant therapy in Melanoma. Semin Oncol 2010;37:455-9
   PubMed Web of Science ®Google Scholar
• Mackiewicz J, Mackiewicz A. Immunotargeting of melanoma. In: Cao MY, editor. Current Management of Malignant Melanoma. InTech; Rijeka: 2011. p. 93-118. Available from: www.intechopen.com
   Google Scholar
• Piantadosi S. Clinical Trials: A Methodologic Perspective. 2nd edition. Wiley; Hoboken, NJ: 2005. Sec. 11.4.7
   Google Scholar
• Mackiewicz A. Vaccine compositions. EP 2 252 322 (2009); Mackiewicz A, Wysocki PJ, Suchorska W. Vaccine compositions. US2011002898; 2010. Available from: www.freepatentsonline.com/y2011/0002898.html
   Google Scholar
• Fisher M, Goldschmitt J, Peschel C, A bioactive designer cytokine for human hematopoetic cell expansion. Nat Biotechnol 1997;15:142-5
   PubMed Web of Science ®Google Scholar
• Therasse P, Arbuck SG, Eisenhauer EA, New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000;92:205-16
   PubMed Web of Science ®Google Scholar
• Collet D. Modelling Survival Data in Medical Research. 2nd edition. Chapman&Hall/CRC; Boca Raton: 2003
   Google Scholar
• Parmiani G, Pilla L, Maccalli C, Russo V. Autologous versus allogeneic cell-based vaccines ? Cancer J 2011;17:331-6
   PubMed Web of Science ®Google Scholar
• Mackiewicz J, Mackiewicz A. Gene-modified cellular vaccines: technologic aspects and clinical problems. Transpl Proc 2010;42:3287-92
   PubMed Web of Science ®Google Scholar
• Morton DL, Mozzilo N, Thomson JF, An international, randomized, phase III trial of baccilus Calmette-Geurin (BCG) plus allogeneic cell vaccine (MCV) or placebo after complete resection of melanoma metsetases to regional or distant sites. J Clin Oncol 2007;25(18 Suppl):abstract 8508
   Google Scholar
• Wysocki PJ, Karczewska-Dzionk A, Mackiewicz-Wysocka M, Mackiewicz A. Human cancer gene therapy with cytokine gene-modified cells. Expert Opin Biol Ther 2004;4:1595-607
   PubMed Web of Science ®Google Scholar
• Arienti F, Belli F, Napolitano F, Vaccination of melanoma patients with interleukin 4 gene-transduced allogeneic melanoma cells. Hum Gene Ther 1999;10:2907-16
   PubMed Web of Science ®Google Scholar
• Osanto S, Schiphorst PP, Weijl NI, Vaccination of melanoma patients with an allogeneic, genetically modified interleukin 2-producing melanoma cell line. Hum Gene Ther 2000;11:739-50
   PubMed Web of Science ®Google Scholar
• Belli F, Arienti F, Sule-Suso J, Active immunization of metastatic melanoma patients with interleukin-2 transduced allogeneic melanoma cells: evaluation of efficacy and tolerability. Cancer Immunol Immunother 1997;44:197-203
   PubMed Web of Science ®Google Scholar
• Maio M, Fonsatti E, Lamaj E, Vaccination of stage IV patients with allogeneic IL-4- or IL-2-gene-transduced melanoma cells generates functional antibodies against vaccinating and autologous melanoma cells. Cancer Immunol Immunother 2002;52:9-14
   Google Scholar
• Nawrocki S, Murawa P, Malicki J, Genetically modified tumour vaccines (GMTV) in melanoma clinical trials. Immunol Lett 2000;74:81-6
   PubMed Web of Science ®Google Scholar
• Korn EL, Liu P-Y, Lee SJ, Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials. J Clin Oncol 2008;26:527-34
   PubMed Web of Science ®Google Scholar
• Mitchel MS, Abrams J, Thompson JA, Randomized trial of an allogeneic melanoma lysate vaccine with low-dose interferon alfa-2b for resected stage III cutaneous melanoma. J Clin Oncol 2007;25:2078-85
   PubMed Web of Science ®Google Scholar
• Hersey P, Caotes AS, McCarthy WH, Adjuvant immunotherapy of patients with high-risk melanoma using vaccinia viral lysates of melanoma. Results of randomized trail. J Clin Oncol 2002;20:4181-90
   PubMed Web of Science ®Google Scholar
• Eggermont AMM, Suciu S, Samtinam M, Adjuvant therapy with pegylated interferon alpha-2b versus observation in resected stage III melanoma. Final results of EORTC 18891, a randomized phase 3 trial. Lancet 2008;372:117-26
   PubMed Web of Science ®Google Scholar
• Eigentler TK, Radny P, Hauschild A, Adjuvant treatment with vindesine in comparison to observation alone in patients with metastasized melanoma after complete metastasectomy: a randomized multicenter trial of the German Dermatologic Cooperative Oncology Group. Melanoma Res 2008;18:363-8
   Web of Science ®Google Scholar
• Bystryn J-C, Zeleniuch-Jacquotte A, Oratz R, Double-blind trial of polyvalent, shed-antigen, melanoma vaccine. Clin Cancer Res 2001;7:1882-7
   PubMed Web of Science ®Google Scholar
• Coventry BJ, Hersey P, Halligan A-M, Immuno-chemotherapy using repeated vaccine treatment can produce successful clinical responses in advanced metastatic melanoma. J Cancer Ther 2010;1:295-13
   Google Scholar
• Hoos A, Parmiani G, Hege K. A clinical development paradigm for cancer vaccines and related biologics. J Immunother 2007;30:1-15
   PubMed Web of Science ®Google Scholar
• Nawrocki S, Mackiewicz A. Clinical trials of active cancer immunotherapy. Expert Opin Investig Drugs 2007;16:1137-41
   PubMed Web of Science ®Google Scholar
• Mackiewicz J, Mackiewicz A. Design of clinical trials for therapeutic cancer vaccines development. Eur J Pharmacol 2009;625:84-9
   PubMed Web of Science ®Google Scholar
• Eggermont MM. Immunostimulation versus immunosuppression after multiple vaccinations: the woes of therapeutic vaccine development. Clin Cancer Res 2009;15:6745-7
   Google Scholar
• Atanackovic D, Altorki NK, Cao Y, Booster vaccination of cancer patients with MAGE-A3 protein reveals long-term immunological memory or tolerance depending on priming. PNAS 2008;105:1650-5
   PubMed Web of Science ®Google Scholar
• Mackiewicz A, Schooltink H, Heinrich P, Rose-John S. Soluble human IL-6-receptor/IL-6 up-regulates expression of acute phase proteins. J Immunol 1992;149:2021-7
   PubMed Web of Science ®Google Scholar
• Mackiewicz A, Wiznerowicz M, Roeb E, Soluble interleukin-6 receptor is biologically active in vivo. Cytokine 1995;7:142-9
   PubMed Web of Science ®Google Scholar
• Izycki D, Nawrocki S, Filas V, IL-6 and soluble IL-6 receptor gene modified tumor vaccine induces more efficient anti-melanoma immune responses and polarizes response towards Th1 type. Pol J Environ Stud 2005;14:139-59
   Google Scholar
• Mackiewicz A, Gorny A, Laciak M, Gene therapy of human melanoma. Immunization of patients with autologous tumor cells admixed with allogeneic melanoma cells secreting interleukin 6 and soluble interleukin 6 receptor. Hum Gene Ther 1995;6:805-11
   PubMed Web of Science ®Google Scholar
• Wysocki PJ, Kazimierczak U, Suchorska W, Gene-modified tumor vaccine secreting Hyper-Interleukin-6 is an effective therapy in mice bearing orthotopic renal cell cancer. Cancer Gen Ther 2010;17:465-75
   PubMed Web of Science ®Google Scholar
• Wolchok JD, Hoos A, O'Day S. Guidelines for evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res 2009;15:7412-20
   PubMed Web of Science ®Google Scholar